As I posted on the yahoo board, the insulin pill is no threat to Afrezza, but rather to basal insulin. The slant of the article is very biased, suggesting Afrezza's future is uncertain. But we all know only the approval and financing are up in the air... the drug works well. Meanwhile, they are so rosy on the pill, when that indeed faces significant hurdles. These being that the drug must survive acids and enzymes in the stomach and then be absorbed in a uniform and consistent manner. This insulin pill is in the early stages. If it does make it through clinical trials (many years down the road), it would make a great basal insulin complement to Afrezza.